Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nefazodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nefazodone SCHEMBL35089 | 1.00 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL6479060 | 1.00 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL27748022 | 0.99 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL30054492 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL27748020 | 0.99 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL5501519 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL8195097 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL41119 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL9275261 | 0.99 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 | |
| Nefazodone SCHEMBL7659683 | 0.98 | DRD2 (0.98) | DRD2HTR2ADRD3HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076461-B1 | LUMATEPERONE FOR USE IN SCHIZOPHRENIA TREATMENT | INTRA CELLULAR THERAPIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250339497-A1 | METHODS FOR TREATING MOOD DISORDERS BY ADMINISTERING A LEPTIN RECEPTOR AGONIST | UNIV DUISBURG ESSEN (DE) | 2025-11-06 | — | — | US | claimed |
| US-20250312293-A1 | ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER | CLEXIO BIOSCIENCES LTD (IL) | 2025-10-09 | — | — | US | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250195454-A1 | METHOD OF TREATING MAJOR DEPRESSIVE DISORDER | CLEXIO BIOSCIENCES LTD. (IL) | 2025-06-19 | — | — | US | claimed |
| US-12280022-B2 | Method of treating major depressive disorder | CLEXIO BIOSCIENCES LTD. (IL) | 2025-04-22 | — | — | US | claimed |
| EP-4536231-A1 | TREATMENT OF ANTIDEPRESSANT RESISTANT SUBJECTS | Actinogen Medical Limited (AU) | 2025-04-16 | — | — | EP | claimed |
| CN-119827657-A | Analysis and detection method for non-neridrone enantiomer | 海化生命(厦门)科技有限公司 | 2025-04-15 | — | — | CN | claimed |
| EP-4504237-A1 | METHODS FOR TREATING MOOD DISORDERS BY ADMINISTERING A LEPTIN RECEPTOR AGONIST | Universität Duisburg-Essen (DE) | 2025-02-12 | — | — | EP | claimed |
| CN-119405616-A | Non-neridrone capsule and preparation method thereof | 杭州和康药业有限公司 | 2025-02-11 | — | — | CN | claimed |
| EP-3570940-B1 | PRIDOPIDINE FOR USE IN THE TREATMENT OF FRAGILE X SYNDROME | Prilenia Neurotherapeutics Ltd (IL) | 2023-12-13 | — | — | EP | claimed |
| WO-2023194571-A1 | METHODS FOR TREATING MOOD DISORDERS BY ADMINISTERING A LEPTIN RECEPTOR AGONIST | Universität Duisburg-Essen (DE) | 2023-10-12 | — | — | WO | claimed |
| EP-3125893-B1 | DEUTERATED HETEROCYCLE FUSED GAMMA-CARBOLINES AS ANTAGONISTS OF 5-HT2A RECEPTORS | INTRA CELLULAR THERAPIES INC (US) | 2023-09-20 | — | — | EP | claimed |
| US-20230248666-A1 | DOSAGE REGIME WITH ESKETAMINE FOR TREATING MAJOR DEPRESSIVE DISORDER | CLEXIO BIOSCIENCES LTD. (IL) | 2023-08-10 | — | — | US | claimed |
| US-20230233486-A1 | DOSAGE REGIME WITH ESKETAMINE FOR TREATING MAJOR DEPRESSIVE DISORDER | CLEXIO BIOSCIENCES LTD. (IL) | 2023-07-27 | — | — | US | claimed |
| US-20230233487-A1 | METHOD OF TREATING MAJOR DEPRESSIVE DISORDER | CLEXIO BIOSCIENCES LTD. (IL) | 2023-07-27 | — | — | US | claimed |
| EP-3197344-B1 | SYSTEMS AND METHODS FOR TREATING A PSYCHIATRIC DISORDER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-05-03 | — | — | EP | claimed |
| EP-3429563-B1 | DESFORMYLFLUSTRABROMINE FOR USE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS | SAINT JOSEPHS UNIV (US) | 2023-04-26 | — | — | EP | claimed |
| EP-3891505-B1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS | REDHOTDIAGNOSTICS AB (SE) | 2022-11-30 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |